StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) income statement

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.05−0.07 (-0.98%)

Close on Nov 20, 2026Market cap $363.92MP/E 13.6Yield –

Puma Biotechnology, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
74.8%
Operating margin
13.2%
Net margin
11.6%
Return on equity, FY2025
28.0%

Financial strength

Current ratio
2.91
Debt to equity
0.00
Debt to assets
0.0%
Cash to current liabilities
73.3%

Valuation

P/E ratio
13.6
Price to sales
1.57
Price to book
2.63
Dividend yield
–

See a number that looks wrong?